EP0998285A4 - ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a - Google Patents

ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a

Info

Publication number
EP0998285A4
EP0998285A4 EP98930356A EP98930356A EP0998285A4 EP 0998285 A4 EP0998285 A4 EP 0998285A4 EP 98930356 A EP98930356 A EP 98930356A EP 98930356 A EP98930356 A EP 98930356A EP 0998285 A4 EP0998285 A4 EP 0998285A4
Authority
EP
European Patent Office
Prior art keywords
alpha
receptor antagonists
adrenergic receptor
adrenergic
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98930356A
Other languages
German (de)
English (en)
Other versions
EP0998285A1 (fr
Inventor
Michael A Patane
Mark G Bock
Harold G Selnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9719392.4A external-priority patent/GB9719392D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0998285A1 publication Critical patent/EP0998285A1/fr
Publication of EP0998285A4 publication Critical patent/EP0998285A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP98930356A 1997-06-18 1998-06-17 ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a Withdrawn EP0998285A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4992197P 1997-06-18 1997-06-18
US49921P 1997-06-18
GBGB9719392.4A GB9719392D0 (en) 1997-09-11 1997-09-11 Alpha la adrenergic receptor antagonists
GB9719392 1997-09-11
PCT/US1998/012673 WO1998057641A1 (fr) 1997-06-18 1998-06-17 ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a

Publications (2)

Publication Number Publication Date
EP0998285A1 EP0998285A1 (fr) 2000-05-10
EP0998285A4 true EP0998285A4 (fr) 2003-01-08

Family

ID=26312232

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98930356A Withdrawn EP0998285A4 (fr) 1997-06-18 1998-06-17 ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a

Country Status (5)

Country Link
EP (1) EP0998285A4 (fr)
JP (1) JP2002505684A (fr)
AU (1) AU734892B2 (fr)
CA (1) CA2293408A1 (fr)
WO (1) WO1998057641A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207444B1 (en) 1997-08-05 2001-03-27 Merck & Co., Inc. Enzymatic process of making alpha 1a adrenergic receptor antagonists using protease
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
AU5234899A (en) 1998-07-30 2000-02-21 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
HU230612B1 (hu) 2002-11-27 2017-04-28 Incyte Corporation Kemokin receptorokat módosító hatású 3-aminopirrolidin-származékok
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
JP5782381B2 (ja) 2008-12-10 2015-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ Ｃｃｒ２の４−アゼチジニル−１−ヘテロアリール−シクロヘキサノールアンタゴニスト
US8324186B2 (en) 2009-04-17 2012-12-04 Janssen Pharmaceutica N.V. 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2
WO2010121046A1 (fr) 2009-04-17 2010-10-21 Janssen Pharmaceutica Nv Antagonistes de ccr2 a base de 4-azetidinyl-1-phenyl-cyclohexane
CA2799640C (fr) 2010-06-09 2018-10-16 Janssen Pharmaceutica Nv Derives de 5,6-dihydro-2h-[1,4]oxazin-3-ylamine utiles comme inhibiteurs de beta-secretase (bace)
TW201211027A (en) * 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
EP2582692B1 (fr) 2010-06-17 2015-07-22 Janssen Pharmaceutica NV Cyclohexyl-azetidines commme inhibiteurs de la ccr2
ES2648143T3 (es) 2010-12-22 2017-12-28 Janssen Pharmaceutica Nv Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8-ilamina útiles como inhibidores de la beta-secretasa (BACE)
JP5853035B2 (ja) 2011-03-09 2016-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な３，４−ジヒドロ−ピロロ［１，２−ａ］ピラジン−１−イルアミン誘導体
JP6083818B2 (ja) 2011-11-18 2017-02-22 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニスト
BR112015030597A2 (pt) 2013-06-12 2017-07-25 Janssen Pharmaceutica Nv derivados 4-amino-6-fenil-6,7-di-hidro[1,2,3]triazolo[1,5-a]pirazina como inibidores de beta-secretase (bace)
MX368326B (es) 2013-06-12 2019-09-27 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace).
US9580433B2 (en) 2013-06-12 2017-02-28 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)
ES2768823T3 (es) 2014-12-18 2020-06-23 Janssen Pharmaceutica Nv Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014846A1 (fr) * 1994-11-16 1996-05-23 Synaptic Pharmaceutical Corporation Dihydropyrimidines et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049821A (en) * 1976-05-12 1977-09-20 A. H. Robins Company, Inc. Method of treating allergy
US4109005A (en) * 1977-05-11 1978-08-22 A. H. Robins Company, Inc. Method of increasing rate of gastric emptying with pyrrolidinylbenzamides
US4254135A (en) * 1979-10-16 1981-03-03 A. H. Robins Company, Inc. 3-Amino-4-hydroxypyrrolidines
US5124457A (en) * 1986-05-21 1992-06-23 Abbott Laboratories Phencyclidine and phencyclidine metabolites assay, tracers, immunogens and antibodies
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014846A1 (fr) * 1994-11-16 1996-05-23 Synaptic Pharmaceutical Corporation Dihydropyrimidines et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9857641A1 *

Also Published As

Publication number Publication date
AU734892B2 (en) 2001-06-28
CA2293408A1 (fr) 1998-12-23
JP2002505684A (ja) 2002-02-19
WO1998057641A1 (fr) 1998-12-23
EP0998285A1 (fr) 2000-05-10
AU7976398A (en) 1999-01-04

Similar Documents

Publication Publication Date Title
EP0998285A4 (fr) ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
EP0822814A4 (fr) ANTAGONISTES DES RECEPTEURS ADRENERGIQUES ALPHA 1a
SG70110A1 (en) Ccr-3 receptor antagonists
ZA988100B (en) IL-8 receptor antagonists
GB9927227D0 (en) CCR-3 receptor antagonists III
IL131004A0 (en) Il-8 receptor antagonists
GB2343891B (en) 4-Aroyl-piperidine CCR-3 receptor antagonists
EP0833637A4 (fr) ANTAGONISTES DU RECEPTEUR ALPHA ADRENERGIQUE 1a
IL130760A0 (en) Vitronectin receptor antagonists
EP1000017A4 (fr) Antagonistes du recepteur il-8
EP0831823A4 (fr) ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
EP0755392A4 (fr) Antagonistes du recepteur adrenergique alpha1c
IL135028A0 (en) Vitronectin receptor antagonists
EP1019052A4 (fr) ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
EP1023068A4 (fr) ANTAGONISTES DES ADRENORECEPTEURS ALPHA 1a
IL131005A0 (en) Il-8 receptor antagonists
EP1014973A4 (fr) ANTAGONISTES DES ADRENORECEPTEURS ALPHA 1a
HK1028730A1 (en) Il-8 receptor antagonists
EP0971908A4 (fr) Antagoniste de recepteurs d'il-8
EP0831824A4 (fr) ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
EP0853479A4 (fr) ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1b
AU5234899A (en) Alpha 1a adrenergic receptor antagonists
GB9719392D0 (en) Alpha la adrenergic receptor antagonists
GB9605165D0 (en) Alpha 1a adrenergic receptor antagonists
GB9719706D0 (en) Alpha 1a adrenergic receptor antagonist

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20021125

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/445 A, 7A 61K 31/505 B, 7C 07D 211/18 B, 7C 07D 239/34 B, 7C 07D 491/08 B, 7C 07D 487/04 B, 7C 07D 401/12 B, 7C 07D 411/12 B, 7C 07D 413/12 B, 7C 07D 401/14 B, 7C 07D 403/12 B, 7C 07D 413/14 B, 7C 07D 403/14 B, 7A 61P 13/08 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030103